Survival among patients cured from gastric adenocarcinoma compared to the background population
Gastric Cancer · 2024
DOI: 10.1007/s10120-024-01545-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Gastric Cancer, 2024. Verfasst von Wilhelm Leijonmarck und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine and Surgery, Karolinska Institutet and Karolinska University Hospital, Retzius Street 13A, 4th, Floor, 171 77, Stock…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Adenocarcinoma, Gastrectomy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vetenskapsrådet, Cancerfonden, Radiumhemmets Forskningsfonder.
Abstract (Originalsprache)
Background
It is unknown if gastric adenocarcinoma survivors have longer, shorter, or similar survival compared to the background population. This knowledge could contribute to evidence-based monitoring strategies, healthcare recommendations, and information for patients and families.
Methods
This population-based cohort study included all patients who underwent gastrectomy for gastric adenocarcinoma between 2006–2015 in Sweden and survived ≥ 5 years after surgery. They were followed up until death, postoperative year 10, or end of study period (31 December, 2020). Division of the observed by the expected survival yielded relative survival rates with 95% confidence intervals (CIs) using the life table method. The expected survival was derived from the entire Swedish population of the corresponding age, sex, and calendar year. Data came from medical records and nationwide registers.
Results
The survival among all 767 gastric adenocarcinoma survivors was shorter than the expected. The reduction in relative survival increased for each follow-up year, from 97.3% (95% CI 95.4–99.1%) year 6 to 86.6% (95% CI 82.3–90.9%) year 10. The decline in relative survival was more pronounced among patients who had gastrectomy in earlier calendar years (82.9% [95% CI 77.4–88.4%] year 10 for years 2011–2015), shorter education (85.2% [95% CI 77.4–93.0%] year 10 for education ≤ 9 years), more comorbidities (78.0% [95% CI 63.9–92.0%] year 10 for Charlson comorbidity score ≥ 2), and no neoadjuvant therapy (83.2% [95% CI 77.4–89.0%] year 10).
Conclusion
Gastric adenocarcinoma survivors seem to have poorer survival than the corresponding background population, particularly in certain subgroups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular Medicine and Surgery, Karolinska Institutet and Karolinska University Hospital, Retzius Street 13A, 4th, Floor, 171 77, Stockholm, Sweden. wilhelm.leijonmarck@ki.se.
- Department of Molecular Medicine and Surgery, Karolinska Institutet and Karolinska University Hospital, Retzius Street 13A, 4th, Floor, 171 77, Stockholm, Sweden.
- School of Cancer and Pharmacological Sciences, King's College London, London, UK.
ORCID-Profile: Wilhelm Leijonmarck
Förderung
- Vetenskapsrådet
- Cancerfonden
- Radiumhemmets Forskningsfonder
- Karolinska Institute
Zitieren
APA
Leijonmarck, W., Mattsson, F., & Lagergren, J. (2024). Survival among patients cured from gastric adenocarcinoma compared to the background population. Gastric Cancer. https://doi.org/10.1007/s10120-024-01545-y
Vancouver
Leijonmarck W, Mattsson F, Lagergren J. Survival among patients cured from gastric adenocarcinoma compared to the background population. Gastric Cancer. 2024. doi:10.1007/s10120-024-01545-y
BibTeX
@article{Leijonmarck2024,
author = {Leijonmarck, Wilhelm and Mattsson, Fredrik and Lagergren, Jesper},
title = {Survival among patients cured from gastric adenocarcinoma compared to the background population},
journal = {Gastric Cancer},
year = {2024},
doi = {10.1007/s10120-024-01545-y}
}
EUVIMED